| Project/Area Number |
26461018
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
Noguchi Ryuichi 奈良県立医科大学, 医学部附属病院, 研究員 (30423908)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
吉治 仁志 奈良県立医科大学, 医学部, 教授 (40336855)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MATSUMOTO MASANORI 奈良県立医科大学, 医学部, 教授 (60316081)
NAMISAKI TADASHI 奈良県立医科大学, 医学部, 講師 (20526850)
MORIYA KEI 奈良県立医科大学, 医学部, 講師 (40526852)
KITADE MITSUTERU 奈良県立医科大学, 医学部, 助教 (40526795)
MASHITANI TSUYOSHI 奈良県立医科大学, 医学部, 助教 (20401929)
|
|---|
| Research Collaborator |
NISHIMURA NORIHISA
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | NASH / 生活習慣病 / ARB / DPP-Ⅳ阻害剤 / SGLT-2阻害剤 / PAI-1阻害剤 / DPP4阻害剤 / PAI-1 / 肝線維化 / 非アルコール性脂肪肝炎 / DPPIV阻害剤 / DPPⅣ阻害剤 / 血管新生 |
|---|
| Outline of Final Research Achievements |
In the rat NASH model, ARB and DPP-IV inhibitor innhibited liver fibrosis along with suppression of activated hepatic stellate cells (Ac-HSCs) and TGF-β expression, and treatment with both drugs further suppressed significantly as compared with either single agent. SGLT-2 inhibitor, which is a drug for treating diabetes mellitus, indirectly suppressed liver fibrosis through the insulin resistance-improving effect. PAI-1 inhibitor markedly inhibited the development of liver fibrosis along with suppression of Ac-HSC. Our in vitro data showed that PAI-I inhibitor directly suppressed proliferation of Ac-HSCs, expression of TGF-β mRNA and α1 collagen mRNA. Furthermore, clinical studies suggested the possibility of DPP-IV inhibitor for treating fatty liver disease with type 2 diabetes.
|
